Dr. Jared Silver, MD, PhD, Allergist Immunologist & Indication Lead for Mepolizumab, US Medical Affairs Respiratory at GSK discusses the recent FDA approval of NUCALA (mepolizumab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. He explains why incorporating a biologic can be an important part of a patient’s treatment plan.
Jared Silver, MD, PhD, Indication Lead for Mepolizumab in CRS w NP, US Medical Affairs Respiratory.
Dr. Silver joined GSK in September 2018 as a Medical Director for Mepolizumab focusing on Severe Eosinophilic Asthma (SEA) and assisting with ongoing work for Hypereosinophilic Syndrome (HES) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). In February 2020, Jared accepted the role of US Lead for Mepolizumab to manage the development of the emerging indication for Mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP).
Jared earned his BS in Biochemistry from the University of North Carolina at Chapel Hill in 2001. He then completed his medical and graduate training at the University of Florida College of Medicine in Gainesville in 2010. His path led to residency in Internal Medicine at the University of Virginia in Charlottesville, concluding in 2013. Dr. Silver then completed fellowship training in Allergy and Immunology at Brigham and Women’s Hospital in 2016. Jared joined the faculty at Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, Harvard Medical School, and Dana Farber Cancer Institute in 2016. Jared has a research background encompassing basic science and translational immunology, with a focus on antibody biology. His clinical interests include asthma, NP disorders (CRSwNP & NSAID Exacerbated Respiratory Disease (NERD)), drug hypersensitivity / desensitization, venom hypersensitivity, and immune deficiency.